A Matching-Adjusted Indirect Comparison of the Efficacy of Bimekizumab and Guselkumab at 52 Weeks for the Treatment of Psoriatic Arthritis. J of Skin 2024, 8 (1), s312. https://doi.org/10.25251/skin.8.supp.312.